Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria
- First Posted Date
- 2015-08-04
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 463
- Registration Number
- NCT02515279
- Locations
- 🇦🇹
A.Ö. Krankenhaus Der Barmherzigen Schwestern Ried; Interne Abtl., Ried-innkreis, Austria
A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
- First Posted Date
- 2015-07-27
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 46
- Registration Number
- NCT02508870
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸City of Hope, Duarte, California, United States
An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With Rituximab
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 94
- Registration Number
- NCT02507752
Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT02508090
- Locations
- 🇵🇷
Fundacion de Investigacion de Diego, San Juan, Puerto Rico
A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 17
- Registration Number
- NCT02507375
Effect of RO6871765 and RO7011785 on Immune Response With the Stimulation of Peripheral Blood Mononuclear Cells (PBMCs) in Chinese Healthy Volunteers and Chronic Hepatitis B Patients
- Conditions
- Hepatitis B, Chronic
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 14
- Registration Number
- NCT02498275
A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 19
- Registration Number
- NCT02494596
A Study of Pertuzumab in Participants With Metastatic Breast Cancer
- First Posted Date
- 2015-07-08
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 79
- Registration Number
- NCT02491892
A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 19
- Registration Number
- NCT02490475
A Study Of Mircera In Patients With Kidney Disease Who Are Not On Dialysis
- Conditions
- Renal Tubular Acidosis, Distal, With Hemolytic Anemia
- Interventions
- Other: No intervention
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2015-08-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 153
- Registration Number
- NCT02490514